2008
DOI: 10.1038/mt.2008.98
|View full text |Cite
|
Sign up to set email alerts
|

Central Delivery of Dicer-substrate siRNA: A Direct Application for Pain Research

Abstract: RNA interference (RNAi) is gaining acceptance as a potential therapeutic strategy against peripheral disease, and several clinical trials are already underway with 21-mer small-interfering RNA (siRNA) as the active pharmaceutical agent. However, for central affliction like pain, such innovating therapies are limited but nevertheless crucial to improve pain research and management. We demonstrate here the proof-of-concept of the use of 27-mer Dicer-substrate siRNA (DsiRNA) for silencing targets related to CNS d… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
37
0

Year Published

2008
2008
2016
2016

Publication Types

Select...
5
4

Relationship

1
8

Authors

Journals

citations
Cited by 51 publications
(38 citation statements)
references
References 49 publications
1
37
0
Order By: Relevance
“…Similarly, 21-mer siRNAs are currently the lead compounds for a number of clinical and preclinical RNAi drug development programs. Alternative designs are also in use for both research and drug development, including blunt 19-mers (Czauderna et al, 2003;Allerson et al, 2005;Prakash et al, 2005;Kraynack and Baker, 2006), blunt 25-mers (Chen et al, 2005), blunt 27-mers , and asymmetric 25/27-mers or 27/29-mers Dore-Savard et al, 2008;Nishina et al, 2008). Some of these compounds directly load into RISC whereas others are substrates for Dicer and are processed into shorter species before RISC loading.…”
Section: The Rationale For Chemical Modifi Cationmentioning
confidence: 99%
“…Similarly, 21-mer siRNAs are currently the lead compounds for a number of clinical and preclinical RNAi drug development programs. Alternative designs are also in use for both research and drug development, including blunt 19-mers (Czauderna et al, 2003;Allerson et al, 2005;Prakash et al, 2005;Kraynack and Baker, 2006), blunt 25-mers (Chen et al, 2005), blunt 27-mers , and asymmetric 25/27-mers or 27/29-mers Dore-Savard et al, 2008;Nishina et al, 2008). Some of these compounds directly load into RISC whereas others are substrates for Dicer and are processed into shorter species before RISC loading.…”
Section: The Rationale For Chemical Modifi Cationmentioning
confidence: 99%
“…For example, RNAi has been used to reduce neuropathic pain, prevent neuronal death induced by brain ischemia, minimize the damage caused by prion proteins, and induce apoptosis or increase chemotherapy susceptibility in brain tumors (Gondi et al 2004;Zhang et al 2004;Pfeifer et al 2006;Dore-Savard et al 2008;White et al 2008;Sun et al 2009). …”
Section: Slow Channel Congenital Myasthenic Syndromementioning
confidence: 99%
“…Indeed, central delivery of stable NT analogs produces dose-dependent antinociception in response to different experimetital pain modalities, including thermal, mechanical, and chemical stimuli (17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27). Accordingly, inhibition of NTSl or NTS2 function by pharmacological NT receptor antagonists, antisense technologies, or generation of knockout animals supports the involvement of these receptors in the regulation of pain processing (19,25,(28)(29)(30)(31)(32)(33)(34). In light of the fact that neuropathic pain conditions are only partially responsive to opioid therapy, it is also important to point out that NT exerts its analgesic effects at least in part through opioid-independent mechanisms (35,36).…”
mentioning
confidence: 99%